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Buprenorphine/naloxone 
 Introduced in 2003 
(Suboxone®) 
 First opioid for addiction 
treatment that can be dispensed 
in an outpatient setting and 
taken without direct observation 
• Considered safer than 
methadone 
• Doses > 24 mg not 
recommended 
Why we are interested in 
Buprenorphine & Medicaid?  
 Medicaid is a key payer for 
buprenorphine treatment 
 Increasing concern about cost 
and diversion of buprenorphine 
 Most states restrict access 
through prior authorization 
requirements 
 
Buprenorphine treatment in 
MassHealth has risen steadily  
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Prior Authorization 
• Prescribers must get authorization 
before a prescription is filled 
• Seeks to reduce cost and/or improve 
safety 
• Typically imposed by an insurer 
• A favorite tool for Medicaid programs 
 
 
Unanticipated Effects 
• Does not always reduce costs 
• May break treatment continuity 
• May contribute to relapse 
(Law et al, 2008; Abouzaid et al 2010; Lu et al. 2011;  
Morden 2008) 
MassHealth* Prior Authorization 
for Suboxone® 
Daily Dose Authorization Frequency 
> 32 mg Each prescription 
> 24 mg & < 32 Every 90 days 
> 16 mg & < 24  Every 180 days 
< 16 mg None required 
•Implemented in January 2008 
•High doses required more frequent authorization 
 
* The Massachusetts Medicaid Program 
Research Questions 
1. Did high-dose treatment decrease? 
2. Did prior authorization affect 
medication costs and total costs? 
3. Did prior authorization affect relapse 
rates? 
 
Methods 
• Medicaid claims January 2007 through 
December of 2008 
• Additional data on other publically 
funded detoxification treatment 
• Limited to those who used Suboxone® 
• Three treatment groups: Low dose < 16 
mg/day, Medium 16-24 mg, High 
>24mg 
Time series 
• Population level analysis 
- analyzed claims for all patients using month 
as the unit of observation 
• Individual level multivariable analysis 
- analyzed claims for continuously enrolled 
patients as the unit of observation (n 
=2,049) 
• Generalized estimating equations for 
both 
Suboxone users in 2007 
Low   
n = 908 
Medium  
n = 699 
High  
n = 442 
Total  
n= 2,049 
Age 32.9  
(9.9) 
33.1  
(9.4) 
34.2  
(9.7) 
33.2  
(9.7) 
% Women 43.1% 37.0% 33.3% 38.9% 
MH 
conditions 
1.4  
(1.5) 
 1.3  
(1.4) 
1.2  
(1.2) 
1.3  
(1.4) 
Physical 
conditions 
0.7  
(1.0) 
0.6  
(0.9) 
0.8  
(1.0) 
0.7  
(1.0) 
Suboxone® 
$/month 
$164  
($96) 
$284  
($128) 
$362  
($179) 
$248  
(151) 
Total 
$/month 
$1,372 
($1,640) 
 
$1,110 
($1,025) 
 
$1,102 
($1,185) 
 
$1,224 
($1,367) 
 
(Standard deviation) 
Suboxone® Doses Before and 
After Prior Authorization 
Cost impact 
• Suboxone® expenditures decreased in 
the high dose group 
• Increased in other groups 
• Net 2008 Suboxone® savings from 
$131,347 to $492,641  
• No savings in overall healthcare costs 
 
 
Temporary Increase in Relapses 
Limitations 
• Measures limited to administrative data 
• Cannot rule out secular (time) effects 
 
Summary 
• The PA effectively lowered high doses 
• Modest decrease in Suboxone® cost 
• No impact on total cost 
• Temporary increase in relapses for 
medium & high dose groups 
• Long-term impact of dose limits needs 
further study 
Why should we care? 
• At least 6 states now place lifetime 
limits on buprenorphine treatment 
• Limiting access to medication-assisted 
treatment can result in more relapses, 
deaths and higher costs 
• Dose related PAs may be a relatively 
safe way to manage “over prescribing” 

